Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II maintenance alemtuzumab in B-cell chronic lymphocytic leukemia
2008-006491-30Phase 2Active
- Sponsor
- Centre Henri Becquerel
- Start
- Mar 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Centre Henri Becquerel. Primary endpoint: Maintenance efficacy rate. Started Mar 2009; status: active.
02
Drugs
alemtuzumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2008-006491-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006491-30.